Key result
The use of antidiabetic drugs with a high risk of hypoglycemia (sulfonylureas or insulin) was significantly associated with an increased risk of coronary heart disease (HR 5.6) in patients with type 2 diabetes.
Why the study?
Under diabetes treatment policies following the Kumamoto Declaration 2013, the JJ risk engine cannot accurately predict complication incidence in patients.
Cohort (n=857)
Yes
Effect estimate: HR 5.6 (95% CI 1.3-24.8)
p-value: p=<0.05
A new prediction equation incorporating the use of sulfonylureas or insulin was successfully developed and externally validated to predict the 5-year incidence of coronary heart disease in Japanese patients with type 2 diabetes.
OBJECTIVE: In the diabetes treatment policy after the Kumamoto Declaration 2013, it is difficult to accurately predict the incidence of complications in patients using the JJ risk engine. This study was conducted to develop a prediction equation suitable for the current diabetes treatment policy using patient data from Kitasato University Kitasato Institute Hospital (Hospital A) and to externally validate the developed equation using patient data from Kitasato University Hospital (Hospital B). Outlier tests were performed on the patient data from Hospital A to exclude the outliers. Prediction equation was developed using the patient data excluding the outliers and was subjected to external validation. RESULTS: By excluding outlier data, we could develop a new prediction equation for the incidence of coronary heart disease (CHD) as a complication of type 2 diabetes, incorporating the use of antidiabetic drugs with a high risk of hypoglycemia. This is the first prediction equation in Japan that incorporates the use of antidiabetic drugs. We believe that it will be useful in preventive medicine for treatment for people at high risk of CHD as a complication of diabetes or other diseases. In the future, we would like to confirm the accuracy of this equation at other facilities.
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2021) conducted a cohort in Type 2 diabetes (n=857). Sulfonylurea and/or insulin use vs. No sulfonylurea or insulin use was evaluated on Incidence of coronary heart disease (CHD) (HR 5.6, 95% CI 1.3-24.8, p=<0.05). The use of antidiabetic drugs with a high risk of hypoglycemia (sulfonylureas or insulin) was significantly associated with an increased risk of coronary heart disease (HR 5.6) in patients with type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: